Effects of netupitant and palonosetron: A Synthesis of Findings from 28 Studies

  1. Home
  2. Effects of netupitant and palonosetron
This information is not medical advice and is not a substitute for diagnosis or treatment by a physician.Data sources and disclaimers (data limitations, copyright, etc.)The analysis on "Effects of netupitant and palonosetron: A Synthesis of Findings from 28 Studies" on this page is based on PubMed data provided by the U.S. National Library of Medicine (NLM). However, NLM does not endorse or verify these analyses.

This analysis is based on research papers included in PubMed, but medical research is constantly evolving and may not fully reflect the latest findings. There may also be biases towards certain research areas.

This information is not medical advice and is not a substitute for diagnosis or treatment by a physician. If you have concerns about "Effects of netupitant and palonosetron: A Synthesis of Findings from 28 Studies", please consult your doctor.

For NLM copyright information, please see Link to NLM Copyright Page
PubMed data is obtained via Hugging Face Datasets: Link to DatasetPlease check the disclaimer.
This page's analysis is based on PubMed data provided by the U.S. National Library of Medicine (NLM).
Original Abstract of the Article

Main Research Findings

Netupitant-palonosetron combination (NEPA) is effective in preventing chemotherapy-induced nausea and vomiting (CINV) in patients receiving multiple cycles of chemotherapy. 24 found that oral NEPA was effective in preventing CINV over multiple chemotherapy cycles. NEPA was also shown to be non-inferior to dexamethasone (DEX) in preventing CINV in patients receiving cisplatin-based chemotherapy. 7 Further, a sub-analysis from a phase 3 study demonstrated that NEPA was effective in preventing CINV in older patients (>65 years) receiving cisplatin-based chemotherapy. 3 In patients with gynecological cancers, NEPA was shown to be effective in preventing CINV after platinum-based chemotherapy. 28 A pragmatic study comparing NEPA to aprepitant for the prevention of CINV in patients receiving moderately emetogenic chemotherapy found that NEPA was more effective in preventing delayed nausea and vomiting associated with cisplatin. 17 In patients with multiple myeloma receiving high-dose melphalan for autologous stem cell transplantation, NEPA without DEX was effective in preventing CINV. 13

Benefits and Risks

Benefits Summary

NEPA has shown to be effective in preventing CINV in various types of chemotherapy regimens, including highly emetogenic and moderately emetogenic chemotherapy. 24 , 7 , 3 , 28 , 17 , 13 It is also well tolerated and has fewer side effects compared to traditional antiemetics. 19 Additionally, NEPA is available in both oral and intravenous formulations, making it a convenient and flexible treatment option for patients. 27

Risks Summary

While generally safe, NEPA may cause side effects in some patients, including constipation, fatigue, headache, and drowsiness. Although rare, serious side effects are also possible. It is important to discuss with your doctor about the potential risks and benefits of NEPA before taking it. 14

Comparison Across Studies

Commonalities

Multiple studies have shown that NEPA is effective in preventing CINV. NEPA is also well tolerated and has fewer side effects compared to traditional antiemetics across these studies. 19 , 14

Differences

The effectiveness and side effect profile of NEPA may vary depending on the type of chemotherapy regimen, patient characteristics, and other factors. 20 For example, in one study, the effectiveness of NEPA was slightly reduced in later cycles of chemotherapy. 20

Consistency and Contradictions in Results

While several studies have consistently shown the effectiveness of NEPA in preventing CINV, there is some inconsistency regarding the long-term effectiveness. 24 , 7 , 3 , 28 , 20 One study suggested that the effectiveness of NEPA may decrease over time, 20 while others have shown that the effectiveness can be maintained over multiple cycles. 24 , 7 Further research is needed to clarify this inconsistency.

Considerations for Real-World Application

NEPA can be a valuable treatment option for patients experiencing CINV. However, it is important to note that it may not be effective for all patients. 14 It is also crucial to consider the potential side effects and discuss them with your doctor. NEPA is a relatively new drug, so long-term safety data is still limited. 23 The effectiveness of NEPA may also vary over time, so it is important to discuss treatment plans with your doctor, especially when receiving multiple cycles of chemotherapy. 20

Limitations of Current Research

There are still limitations to the current research on NEPA. More research is needed to understand the long-term safety and effectiveness of NEPA in different patient populations and for various types of chemotherapy. Further studies are also needed to compare NEPA with other antiemetic options. 9

Future Directions for Research

Future research should focus on evaluating the long-term safety and effectiveness of NEPA in different patient populations. 23 Studies comparing NEPA to other antiemetics are also needed to better understand its role in the management of CINV. 9 Additionally, research on optimizing the dosage and administration of NEPA is crucial. 26

Conclusion

NEPA is an effective and well-tolerated treatment option for preventing CINV in patients receiving chemotherapy. However, it is not effective for all patients, and side effects are possible. 19 , 14 , 21 It is important to discuss with your doctor about the potential risks and benefits of NEPA before taking it. More research is needed to fully understand the long-term safety and effectiveness of NEPA in different patient populations. 23 , 9 Overall, NEPA represents a promising treatment option for improving the quality of life of patients receiving chemotherapy. 8

Literature analysis of 28 papers
Positive Content
27
Neutral Content
0
Negative Content
1
Article Type
6
1
1
4
28
1.

Effect of nicotine lozenges on affective smoking withdrawal symptoms: secondary analysis of a randomized, double-blind, placebo-controlled clinical trial.

Author: ShiffmanSaul

Reduced craving
Reduced distress

Nicotine lozenges significantly reduced affective withdrawal symptoms in high-dependence smokers, with lozenge-related decreases in craving partially mediating the effect of treatment on abstinence, particularly in high-dependence smokers.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

2.

[Translated article] Have changes concerning carboplatin and anthracyclines been incorporated?

Author: CapafonsSusana Redondo, GutierrezLaura Soriano, PortulasElsa Dalmau, MuñozÀlex Barragán, RoblesSergio Martínez, Gómez-ValentMònica

Cost savings
Emesis control

This study aims to analyze the concordance between antiemetic prophylaxis used in clinical practice and the MASCC/ESMO guidelines for moderately emetogenic chemotherapy, evaluate its effectiveness, and assess cost savings using netupitant/palonosetron compared to fosaprepitant.

Observational StudyResearch that observes and collects data on participants' behavior and outcomes in their natural state, without intervention.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

3.

Dexamethasone-sparing regimens with NEPA (netupitant/palonosetron) for the prevention of chemotherapy-induced nausea and vomiting in older patients (>65 years) fit for cisplatin: A sub-analysis from a phase 3 study.

Author: CelioLuigi, BartschRupert, AaproMatti

Chemotherapy-induced nausea
Chemotherapy-induced vomiting

This study evaluated the efficacy of two dexamethasone (DEX)-sparing regimens with an oral fixed-combination of netupitant and palonosetron (NEPA) in older patients who received cisplatin chemotherapy. The regimens were found to be effective in preventing chemotherapy-induced nausea and vomiting in this patient population.

Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

4.

Antiemetic guidelines: Have we incorporated the changes concerning carboplatin and anthracyclines?

Author: Redondo CapafonsSusana, Soriano GutierrezLaura, Dalmau PortulasElsa, Barragán MuñozÀlex, Martínez RoblesSergio, Gómez-ValentMònica

Emesis control

This study analyzed the concordance between guidelines and antiemetic prophylaxis used for highly emetogenic chemotherapy (HEC) and carboplatin in a Chemotherapy Outpatient Unit. It evaluated the effectiveness of netupitant/palonosetron (NEPA) with dexamethasone (NEPAd) compared to fosaprepitant with ondansetron and dexamethasone (FOD iv).

Observational StudyResearch that observes and collects data on participants' behavior and outcomes in their natural state, without intervention.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

6.

Cost-effectiveness analysis of NEPA, a fixed-dose combination of netupitant and palonosetron, for the prevention of highly emetogenic chemotherapy-induced nausea and vomiting: an international perspective.

Author: NilssonJonas, PiovesanaVittoria, TuriniMarco, LezziClaudio, ErikssonJennifer, AaproMatti

Cost-effective

This study assessed the cost-effectiveness of NEPA, a fixed-dose combination of oral netupitant and palonosetron, compared to available treatments in Spain.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

7.

Evaluating the impact of chemotherapy-induced nausea and vomiting on daily functioning in patients receiving dexamethasone-sparing antiemetic regimens with NEPA (netupitant/palonosetron) in the cisplatin setting: results from a randomized phase 3 study.

Author: CelioLuigi, CortinovisDiego, CogoniAlessio Aligi, CavannaLuigi, MartelliOlga, CarnioSimona, CollovàElena, BertoliniFederica, PetrelliFausto, CassanoAlessandra, ChiariRita, ZanelliFrancesca, PiscontiSalvatore, VittimbergaIsabella, LetiziaAntonietta, MisinoAndrea, GernoneAngela, BonizzoniErminio, PilottoSara, De PlacidoSabino, BriaEmilio

Emesis control
Improved quality of life

This study assessed the impact of emesis on the daily lives of patients receiving DEX-sparing regimens using the FLIE scale, providing additional data on the non-inferiority of DEX-sparing regimens compared to standard DEX use in cisplatin-treated patients.

Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Language : English

8.

Netupitant-palonosetron (NEPA) for Preventing Chemotherapy-induced Nausea and Vomiting: From Clinical Trials to Daily Practice.

Author: AaproMatti, JordanKarin, ScottéFlorian, CelioLuigi, KarthausMeinolf, RoelandEric

Improved quality of life
Prevent CINV

This review explores the role of NEPA, a fixed combination antiemetic, in managing chemotherapy-induced nausea and vomiting (CINV). It highlights the benefits of NEPA for improving adherence to guidelines and quality of life for cancer patients.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

9.

Antiemetics for adults for prevention of nausea and vomiting caused by moderately or highly emetogenic chemotherapy: a network meta-analysis.

Author: PiechottaVanessa, AdamsAnne, HaqueMadhuri, ScheckelBenjamin, KreuzbergerNina, MonsefIna, JordanKarin, KuhrKathrin, SkoetzNicole

CINV prevention

This network meta-analysis compared the effects of antiemetic treatment combinations including neurokinin-1 (NK₁) receptor antagonists, 5-hydroxytryptamine-3 (5-HT₃) receptor antagonists, and corticosteroids on prevention of chemotherapy-induced nausea and vomiting (CINV) in adults receiving highly emetogenic chemotherapy (HEC) or moderately emetogenic chemotherapy (MEC).

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Meta-AnalysisA statistical technique that integrates the results of multiple studies to draw more general conclusions about a particular issue.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.
Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.

Language : English

10.

Efficacy and safety of netupitant/palonosetron combination (NEPA) in preventing nausea and vomiting in non-Hodgkin's lymphoma patients undergoing to chemomobilization before autologous stem cell transplantation.

Author: Di RenzoNicola, MussoMaurizio, ScimèRosanna, CupriAlessandra, PerroneTommasina, De RisiClara, PastoreDomenico, GuariniAttilio, MengarelliAndrea, BenedettiFabio, MazzaPatrizio, CapriaSaveria, ChiusoloPatrizia, CupelliLuca, FedericoVincenzo, BozzoliValentina, MessaAnna Rita, MateraRosella, SeripaDavide, CodegaPaolo, BonizzoniErminio, SpecchiaGiorgina

CINV prevention

This study evaluates the effectiveness of antiemetic use during chemomobilization prior to autologous stem cell transplantation (ASCT) for patients receiving highly emetogenic preparative regimens. While studies have shown effective prevention of CINV during the conditioning phase with NK<sub>1</sub>RA-containing regimens, there have been no studies evaluating antiemetic use during chemomobilization prior to ASCT.

Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.

Language : English

11.

Quality of Life Associated with Nausea and Vomiting from Anthracycline-Based Chemotherapy: A Pooled Data Analysis from Three Prospective Trials.

Author: YeoWinnie, MoFrankie K F, YipChristopher C H, YeoVictoria A, LiLeung, LauThomas K H, LaiKwai T, ChanVicky T C, WongKwan H, PangElizabeth, CheungMaggie, ChanVivian, KwokCarol C H, SuenJoyce J S, MolassiotisAlex

Nausea
Vomiting

Chemotherapy-induced nausea and vomiting (CINV) can significantly impact the quality of life (QoL) of patients receiving adriamycin-cyclophosphamide (AC) therapy for breast cancer. This study investigated the impact of CINV on QoL during multiple cycles of AC therapy, examining the pattern of changes in QoL and the potential influence of QoL in an earlier cycle on subsequent cycles.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

13.

Netupitant/palonosetron without dexamethasone for preventing nausea and vomiting in patients with multiple myeloma receiving high-dose melphalan for autologous stem cell transplantation: a single-center experience.

Author: LotetaBarbara, PaviglianitiAnnalisa, NasoVirginia, FerreriAnna, MoscatoTiziana, ConsoleGiuseppe, CanaleFilippo Antonio, IrreraGiuseppe, PuglieseMarta, Di CostanzoAntonella, ProvenzanoPasquale Fabio, LoddoViviana, PortoGaetana, CusumanoGiuseppa, RussoLetteria, MeliambroNicola, RomeoValentina, PorcinoDomenico, GalloSalvatore, GangemiTiziana, RossettiAntonio Maria, MartinoMassimo

CINV prevention

This study investigates the effectiveness of Netupitant/palonosetron (NEPA) in preventing nausea and vomiting in patients with multiple myeloma who are undergoing stem cell transplantation. NEPA was given without Dexamethasone, which is a common antiemetic medication. The study found that NEPA was effective and well-tolerated in this group of patients.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

15.

A Pragmatic Study Evaluating NEPA Versus Aprepitant for Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients Receiving Moderately Emetogenic Chemotherapy.

Author: ZelekLaurent, DebourdeauPhilippe, BourgeoisHugues, WagnerJean Philippe, BrocardFabien, Lefeuvre-PlesseClaudia, ChauffertBruno, LeheurteurMarianne, BachetJean-Baptiste, SimonHélène, MayeurDidier, ScottéFlorian

Prevent CINV

This study compares the efficacy of two neurokinin (NK) 1 receptor antagonists (RAs), netupitant and aprepitant, in patients receiving moderately emetogenic chemotherapy (MEC).

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

16.

Dexamethasone-Sparing Regimens with Oral Netupitant and Palonosetron for the Prevention of Emesis Caused by High-Dose Cisplatin: A Randomized Noninferiority Study.

Author: CelioLuigi, CortinovisDiego, CogoniAlessio Aligi, CavannaLuigi, MartelliOlga, CarnioSimona, CollovàElena, BertoliniFederica, PetrelliFausto, CassanoAlessandra, ChiariRita, ZanelliFrancesca, PiscontiSalvatore, VittimbergaIsabella, LetiziaAntonietta, MisinoAndrea, GernoneAngela, BonizzoniErminio, PilottoSara, De PlacidoSabino, BriaEmilio

Cisplatin-based chemotherapy
Reduce DEX exposure

This study evaluated a new approach to reduce the overall amount of dexamethasone (DEX) used in patients receiving chemotherapy with cisplatin. The study compared the effectiveness of giving DEX on the first day of treatment, with or without low-dose DEX on the following days, to the standard practice of giving DEX for four days. The study found that the shorter DEX regimen was non-inferior to the standard regimen, suggesting that this new approach could potentially reduce the risk of side effects associated with DEX exposure.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

17.

Single-dose netupitant/palonosetron versus 3-day aprepitant for preventing chemotherapy-induced nausea and vomiting: a pooled analysis.

Author: NavariRudolph M, BinderGary, BonizzoniErminio, Clark-SnowRebecca, OlivariSilvia, RoelandEric J

Prevent delayed nausea and vomiting

Guidelines often consider different neurokinin 1 receptor antagonists (RAs) as interchangeable, but no comparative studies exist. This pooled analysis of three cisplatin trials compared the efficacy of netupitant/palonosetron (NEPA) with aprepitant (APR). NEPA, a fixed combination of a neurokinin 1 RA and a serotonin 5-HT3 RA, was more effective than APR in preventing delayed nausea and vomiting after cisplatin chemotherapy.

Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

18.

Capsule-related dysphagia and the use of netupitant/palonosetron (Akynzeo™) capsules - A report of two cases and a solution.

Author: BehbahanyKevin, BubaloJoseph

CINV prevention

This case report describes two patients who experienced difficulty swallowing the netupitant/palonosetron (NEPA) capsule. The study found that the efficacy of NEPA was maintained when the opened capsule was administered as individual medications.

Case ReportsIn the medical field, a report that describes in detail a unique case, an unusual medical condition, or the effect of a treatment. Provides new insights and possibilities for treatment through individual patient cases.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

19.

Management of Chemotherapy-Induced Nausea and Vomiting (CINV): A Short Review on the Role of Netupitant-Palonosetron (NEPA).

Author: LorussoVito, RussoAnna, GiottaFrancesco, CodegaPaolo

CINV prophylaxis

NEPA, a fixed combination antiemetic containing the 5HT3 receptor antagonist palonosetron and the NK1 receptor antagonist netupitant, is used to prevent chemotherapy-induced nausea and vomiting.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

20.

Netupitant/palonosetron (NEPA) and dexamethasone for prevention of emesis in breast cancer patients receiving adjuvant anthracycline plus cyclophosphamide: a multi-cycle, phase II study.

Author: CaputoRoberta, CazzanigaMarina Elena, SbranaAndrea, TorrisiRosalba, ParisIda, GiordanoMonica, MontesarchioVincenzo, GuarneriValentina, AmaducciLaura, BilanciaDomenico, CilentiGiuseppina, FabiAlessandra, CollovàElena, SchironeAlessio, BonizzoniErminio, CelioLuigi, De PlacidoSabino, De LaurentiisMichelino

Chemotherapy-induced nausea treatment
Chemotherapy-induced vomiting treatment

NEPA, an oral fixed-dose combination of netupitant and palonosetron, is effective for preventing chemotherapy-induced nausea and vomiting (CINV). This study found that NEPA's efficacy in cycle 1 was maintained over subsequent chemotherapy cycles in breast cancer patients receiving adjuvant anthracycline plus cyclophosphamide (AC).

Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.

Language : English

21.

NEPA efficacy and tolerability during (neo)adjuvant breast cancer chemotherapy with cyclophosphamide and doxorubicin.

Author: YeoWinnie, LauThomas Kh, KwokCarol Ch, LaiKwai T, ChanVicky Tc, LiLeung, ChanVivian, WongAshley, SooWinnie Mt, YeungEva Wm, WongKam H, TangNelson Ls, SuenJoyce Js, MoFrankie Kf

CINV control

This prospective study evaluated the efficacy and safety of netupitant/palonosetron (NEPA) in controlling chemotherapy-induced nausea and vomiting (CINV) in patients with breast cancer who received (neo)adjuvant AC chemotherapy.

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

22.

Improving Nausea and Vomiting Post-Elipse Balloon: a Novel Single-Dose Regimen of 300 mg Netupitant/0.5 mg Palonosetron Hydrochloride.

Author: IencaR, GiardielloC, ScozzarroA, di ColaR Schiano, Di LorenzoN, JunejaGirish, LopezG, BadiuddinF

Nausea relief
Vomiting relief

This study explored alternative pharmacological options for treating nausea and vomiting after intragastric balloon placement, as ondansetron and prokinetic agents have shown limited effectiveness.

Controlled Clinical TrialA clinical trial that evaluates the effectiveness of a treatment by comparing a group that receives the intervention with a group that receives a placebo or standard treatment.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.

Language : English

24.

Fixed combination of oral NEPA (netupitant-palonosetron) for the prevention of acute and delayed chemotherapy-induced nausea and vomiting in patients receiving multiple cycles of chemotherapy: Efficacy data from 2 randomized, double-blind phase III studies.

Author: SchwartzbergLee, KarthausMeinolf, RossiGiorgia, RizziGiada, BorroniMaria E, RugoHope S, JordanKarin, HansenVincent

CINV prevention
No side effects reported

Oral NEPA (netupitant-palonosetron) was highly effective in preventing chemotherapy-induced nausea and vomiting (CINV) over multiple chemotherapy cycles. NEPA was superior to palonosetron in preventing CINV across 4 cycles of anthracycline-cyclophosphamide (AC)-based chemotherapy.

Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

28.

Efficacy and Safety of Oral NEPA (Netupitant/Palonosetron), the First Fixed-Combination Antiemetic, in Patients With Gynecological Cancers Receiving Platinum-Based Chemotherapy.

Author: BošnjakSnežana M, StamatovicLjiljana, BorroniMaria Elisa, RizziGiada, JordanKarin

Reduced nausea
Reduced vomiting

This post hoc subset analysis evaluated the efficacy of oral NEPA (300-mg netupitant, 0.50-mg palonosetron) in preventing chemotherapy-induced nausea and vomiting (CINV) in patients with gynecological cancer receiving cisplatin- or carboplatin-based chemotherapy.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.